SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
Gregory Gorgas, CEO of Artelo Biosciences, is scheduled to present on September 13, 2023 at 2:00 PM Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed at https://journey.ct.events/view/a3fb36ce-8e0f-41c1-b530-feebded86361 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact [email protected].
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Email: [email protected]